ELUTIA INC. (ELUT) Latest Filing Signal

Latest Filing: 10-K  |  Filed Mar 13, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for ELUTIA INC.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, ELUTIA INC.'s filing signal turned positive.
earningsVibe SuperAnalyst™ Verdict: TURNED POSITIVE

Signal Performance — Stock Price Since Filing

30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Turned Positive
GEMINI
Turned Positive
CLAUDE
Turned Positive
CHATGPT
Continuing Negative

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does ELUTIA INC. actually do?
Answer:
Elutia Inc. is a commercial-stage company focused on developing proprietary drug-eluting biomatrix products for surgical reconstruction and related applications, aiming to improve patient outcomes by reducing surgical complications. The company's strategy centers on its drug-eluting biomatrix (DEB) platform, which integrates biologic matrices with localized drug delivery to address issues like infection and inflammation. Elutia's lead development programs are NXT-41 and NXT-41x, designed for reconstructive surgery. The company continues to market its existing SimpliDerm (human acellular dermal matrix) for soft tissue reconstruction and its cardiovascular repair portfolio, which includes ProxiCor, VasCure, and Tyke. In October 2025, Elutia divested its cardiac implantable electronic device (CIED) business, which included EluPro and CanGaroo products, to Boston Scientific Corporation and Cardiac Pacemakers Inc. for up to $88 million.
Question:
What are ELUTIA INC.'s revenue drivers?
Answer:
Revenue is generated from the sale of SimpliDerm for soft tissue reconstruction and its cardiovascular repair portfolio (ProxiCor, VasCure, Tyke).

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required